About this trial
Dengue virus (DENV) belongs to the genus of Flavivirus transmitted by the mosquito Aedes aegypti and is responsible for an infectious disease associated with different forms and severities such as dengue hemorrhagic fever or shock syndrome. Several recent reports have shown that sickle cell patients exhibited an increased risk of developing severe forms of dengue episodes compared to non-sickle cell subjects. Furthermore, among major sickle cell syndromes, these studies suggest that SC patients are at the highest risk of death during these infectious episodes although this sickle cell syndrome is generally associated with a more moderate expression of sickle cell disease. However, the mechanisms involved remain unknown to date.
The aim of the present study is to identify the molecular and cellular basis of this increased severity of dengue in SC patients. We hypothesize an exacerbation during DENV infection of the inflammatory response in SC patients compared to SS patients.
Eligibility criteria
Qualifiers
patients with SS or SC SCD or controls with hemoglobin AA
diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies
patients older than 6 years and younger than 25 at inclusion
clinically in a steady state at inclusion (without complication during the last month and without transfusion in the three last months)
Disqualifiers
patients with SS or SC SCD or controls with hemoglobin AA
diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies
patients older than 6 years and younger than 25 at inclusion
clinically in a steady state at inclusion (without complication during the last month and without transfusion in the three last months)
Trial design
Treatments tested in this trial
- Not listed